重庆医科大学学报
重慶醫科大學學報
중경의과대학학보
UNIVERSITATIS SCIENTIAE MEDICINAE CHONGQING
2010年
2期
238-240
,共3页
周芸帆%杨刚毅%李伶%刘东方%郭常辉%李生兵%陈文雯
週蕓帆%楊剛毅%李伶%劉東方%郭常輝%李生兵%陳文雯
주예범%양강의%리령%류동방%곽상휘%리생병%진문문
重组人甲状旁腺素%降钙素%骨质疏松症%骨密度
重組人甲狀徬腺素%降鈣素%骨質疏鬆癥%骨密度
중조인갑상방선소%강개소%골질소송증%골밀도
rhPTH(1-34)%Calcitonin%Osteoporosis%Bone mineral density
目的:观察对比重组人甲状旁腺素(1-34)[Recombinant human parat-hyroid hormone,rhPTH(1-34)],后简称PTHI和降钙素(calcitionin,CT)对绝经后妇女骨质疏松症的疗效.方法:符合入选标准的56例绝经后妇女骨质疏松患者随机分为两组:PTH组(n=30)皮下注射重组人甲状旁腺素20 μg每天1次;CT组(n=26)肌肉注射降钙素20 Iu每周1次,两组均每日给予钙尔奇D 600mg/d,连续治疗6个月.比较治疗前后腰椎(L_(2~4))骨密度及T值,血钙磷及碱性磷酸酶(Alkaline phosphatase,AKP)等指标的变化及观察有无不良反应.结果:治疗后PTH组和CT组腰椎(L_(2~4))骨密度(Bone mineral density,BMD)均有明显增加[PTH组:(-4.09±1.30 vs-3.70±1.17)SD;CT组:(-4.03±1.27 vs-3.74±1.19)SD,均P<0.01].但两组间比较无明显差异.PTH组治疗后AKP明显增高[(88.2±28.2vs 123.2±34.2)U/L,P<0.05],而CT组无明显变化.另外,CT组治疗后血清胆固醇(Total cholesterol,TC)降低[(5.64±0.61 vs 5.22±0.70)mmol/L,P<0.O1].两组均无严重不良反应发生.结论:rhPTH(1-34)与降钙素都能显著提高BMD和缓解骨质疏松症状,对于治疗骨质疏松安全有效.
目的:觀察對比重組人甲狀徬腺素(1-34)[Recombinant human parat-hyroid hormone,rhPTH(1-34)],後簡稱PTHI和降鈣素(calcitionin,CT)對絕經後婦女骨質疏鬆癥的療效.方法:符閤入選標準的56例絕經後婦女骨質疏鬆患者隨機分為兩組:PTH組(n=30)皮下註射重組人甲狀徬腺素20 μg每天1次;CT組(n=26)肌肉註射降鈣素20 Iu每週1次,兩組均每日給予鈣爾奇D 600mg/d,連續治療6箇月.比較治療前後腰椎(L_(2~4))骨密度及T值,血鈣燐及堿性燐痠酶(Alkaline phosphatase,AKP)等指標的變化及觀察有無不良反應.結果:治療後PTH組和CT組腰椎(L_(2~4))骨密度(Bone mineral density,BMD)均有明顯增加[PTH組:(-4.09±1.30 vs-3.70±1.17)SD;CT組:(-4.03±1.27 vs-3.74±1.19)SD,均P<0.01].但兩組間比較無明顯差異.PTH組治療後AKP明顯增高[(88.2±28.2vs 123.2±34.2)U/L,P<0.05],而CT組無明顯變化.另外,CT組治療後血清膽固醇(Total cholesterol,TC)降低[(5.64±0.61 vs 5.22±0.70)mmol/L,P<0.O1].兩組均無嚴重不良反應髮生.結論:rhPTH(1-34)與降鈣素都能顯著提高BMD和緩解骨質疏鬆癥狀,對于治療骨質疏鬆安全有效.
목적:관찰대비중조인갑상방선소(1-34)[Recombinant human parat-hyroid hormone,rhPTH(1-34)],후간칭PTHI화강개소(calcitionin,CT)대절경후부녀골질소송증적료효.방법:부합입선표준적56례절경후부녀골질소송환자수궤분위량조:PTH조(n=30)피하주사중조인갑상방선소20 μg매천1차;CT조(n=26)기육주사강개소20 Iu매주1차,량조균매일급여개이기D 600mg/d,련속치료6개월.비교치료전후요추(L_(2~4))골밀도급T치,혈개린급감성린산매(Alkaline phosphatase,AKP)등지표적변화급관찰유무불량반응.결과:치료후PTH조화CT조요추(L_(2~4))골밀도(Bone mineral density,BMD)균유명현증가[PTH조:(-4.09±1.30 vs-3.70±1.17)SD;CT조:(-4.03±1.27 vs-3.74±1.19)SD,균P<0.01].단량조간비교무명현차이.PTH조치료후AKP명현증고[(88.2±28.2vs 123.2±34.2)U/L,P<0.05],이CT조무명현변화.령외,CT조치료후혈청담고순(Total cholesterol,TC)강저[(5.64±0.61 vs 5.22±0.70)mmol/L,P<0.O1].량조균무엄중불량반응발생.결론:rhPTH(1-34)여강개소도능현저제고BMD화완해골질소송증상,대우치료골질소송안전유효.
Objective:To observe the therapeutic effects of recombinant human parathyroid hormone[rhPTH(1-34)]and ealcitonin on post-menopausal women with osteoporosis.Methods:56 postmenopausal women with osteoporosis were randomly divided in to PTH (n=30) and CT (n=26) groups.The patients in PTH group were treated with rhPTH(1-34)20μs/d by subcutaneous injection,and those in CT group were treated with calcitonin 20 IU/week by intramuscular injection.All patients were given oral calcium (Ca 600 mg+Vit D3 125 U.QD).All the treatments lasted for six months.Lumbar spine(L_(2~4)) bone mineral density (BMD),T value,serum calcium,serum phosphate and serum alkline phosphatase were in two groups before and after treatment.Results:In two groups BMD was.remarkably increased after treatment[PTH:(0.74±0.09 vs 0.76±0.08)g/cm~2;CT:(0.74±0.09 vs 0.76 ±0.09)g/cm~2,P<0.01].T-Scores were also significantly increased after treatment[PTH:(-4.09±1.30vs-3.70±1.17)SD,CT:(-4.03±1.27 vs-3.74±1.19)SD,P<0.01].But there were no significant differences between two groups.After treatment,AKP levels were obviously increased in PTH group[(88.2±28.2 vs 123.2±34.2)U/L,P<0.05],whereas serum cholesterol significantly decreased in CT group[(5.64±0.61 vs 5.22±0.70)mmol/L,P<0.01].Conclusion:Both rhPTH(1-34) and calcitonin treatment can increase lumbar spine BMD and relievesymptoms in patients with osteoporosis.